에 대한 최신 뉴스 Bruker (NASDAQ:BRKR) 주식

BRUKER CORP

Bruker

Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.

Red,Stock,Market,Price,Showing,Trader,Phobia,Of,Crisis,War

News

Movers

ANET

ASML

BRKR

COIN

JBHT

MSTR

TSLA

지난주 이들 11개 대형주는 최하의 성과를 보여주었다. 여러분이 보유한 포트폴리오에도 이들이 있나요? Arm 홀딩스(NASDAQ:ARM)는 지난주 가장 성과가 나쁜 대형주 기업으로 31.08% 폭락했다. 이 회사의 주가는 ASML 홀딩 N.V. (NASDAQ:ASML)이 예상보다 저조한 1분기 연간 실적 발표에 영향을 받았다.

지난주 최하 성과 주식: 이 11개의 대형주가 포트폴리오에 있나요?

Bruker Corp

UBS analyst Dan Leonard maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Neutral and lowers the price target from $57 to $45.

Price Target

Analyst Ratings

UBS Maintains Neutral on Bruker, Lowers Price Target to $45

Barclays analyst Luke Sergott maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Overweight and lowers the price target from $50 to $46.

Barclays Maintains Overweight on Bruker, Lowers Price Target to $46

Goldman Sachs analyst Matthew Sykes maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Neutral and lowers the price target from $50 to $45.

Goldman Sachs Maintains Neutral on Bruker, Lowers Price Target to $45

Stifel analyst Daniel Arias maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Hold and lowers the price target from $57 to $48.

Stifel Maintains Hold on Bruker, Lowers Price Target to $48

Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) lowers FY2025 Adj EPS guidance from $2.67-$2.72 to $2.40-$2.48 vs $2.61 analyst estimate. Raises FY2025 sales outlook from $3.47 billion-$3.54 billion to $3.48 billion-$3.55 billion vs $3.48 billion estimate.

Guidance

Bruker Lowers FY2025 Adj EPS Guidance from $2.67-$2.72 to $2.40-$2.48 vs $2.61 Est; Raises FY2025 Sales Guidance from $3.47B-$3.54B to $3.48B-$3.55B vs $3.48B Est

Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $0.43 by 9.3 percent. This is a 11.32 percent decrease over earnings of $0.53 per share from the same period last year. The company reported quarterly sales of $801.40 million which beat the analyst consensus estimate of $764.56 million by 4.82 percent. This is a 11.04 percent increase over sales of $721.70 million the same period last year.

Earnings

Earnings Beats

Bruker Q1 Adj. EPS $0.47 Beats $0.43 Estimate, Sales $801.40M Beat $764.56M Estimate

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

Bruker Says It Will Showcase Major Spatial Biology And Multiomics Innovations At AACR 2025, Highlighting CosMx WTX And 1,200-Plex Protein Panel

Across the recent three months, 6 analysts have shared their insights on Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $57.0, with a high estimate of $65.00 and a low estimate of $50.00. Observing a downward trend, the current average is 17.39% lower than the prior average price target of $69.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1744923614_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Bruker among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Brandon Couillard &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $60.00&#x7C;$75.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $50.00&#x7C;$60.00 &#x7C; 
&#x7C;Patrick Donnelly &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $50.00&#x7C;$75.00 &#x7C; 
&#x7C;Daniel Arias &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $57.00&#x7C;$70.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $60.00&#x7C;$65.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $65.00&#x7C;$69.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bruker. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Bruker compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Bruker's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Bruker's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BRKR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Bruker analyst ratings.</a>
<h2>Delving into Bruker's Background</h2>
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
<h3>Key Indicators: Bruker's Financial Health</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Bruker showcased positive performance, achieving a revenue growth rate of 14.64% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Bruker's net margin excels beyond industry benchmarks, reaching 1.4%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Bruker's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.76%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Bruker's ROA excels beyond industry benchmarks, reaching 0.23%. This signifies efficient management of assets and strong financial health.
Debt Management: Bruker's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.26, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Bruker Through 6 Analysts

Wells Fargo analyst Brandon Couillard maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Overweight and lowers the price target from $75 to $60.

Wells Fargo Maintains Overweight on Bruker, Lowers Price Target to $60

Bruker and RECIPE are pioneering the high-throughput ‘chrom-free' ClinDART triple-quad MS platform for robust and cost-effective therapeutic drug monitoring assays

Bruker Acquires Majority Stake In RECIPE to Advance Chrom-Free Triple-Quad Assays For Therapeutic Drug Monitoring

Bruker Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) reported preliminary revenue Friday for the first quarter that ended March 31, 2025, of $795 million to $800 million compared to a consensus of $758.85 million.
The company&#8217;s sales reflect around 10-11% year-over-year <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44759082/bruker-announces-first-quarter-2025-preliminary-revenue" rel="noreferrer noopener">increase from $721.70 million</a>.
Bruker Corporation is an American manufacturer of scientific instruments for molecular and materials research and industrial and applied analysis.
This estimated range implies a reported revenue growth of approximately 10% year over year, with low double-digit percentage constant exchange rate revenue growth.
Bruker estimates adjusted organic revenue growth in the first quarter to be in the low single-digit percentages, with mid-single-digit percentage organic revenue growth in the Bruker Scientific Instrument (BSI) segment and a high-teens percentage organic revenue decline in the Bruker Energy &amp; Supercon Technologies (BEST) segment, net of intercompany eliminations.
Concurrently, at the ESCMID Global 2025 conference, Bruker&#8217;s Microbiology and Infection Diagnostics division is announcing the expansion of its microbiology solutions into Next-Generation Sequencing (NGS) applications, with new, research-use-only NGS-based solutions in epidemiology and hospital-acquired infection (HAI) tracing.
On Friday, Bruker entered into a strategic collaboration with Ridom GmbH, based in Muenster, Germany, for NGS bioinformatics applications in microbiology <a href="https://www.benzinga.com/pressreleases/25/04/b44757010/bruker-complements-fast-cost-effective-ir-biotyper-hospital-hygiene-testing-and-hai-tracing-with-n" target="_blank" rel="noopener">and infectious disease testing</a>.
Ridom&#8217;s NGS bioinformatics software&nbsp;SeqSphere+&nbsp;is designed for genomic bacterial strain differentiation, multilocus sequence typing (MLST), core genome MLST (cgMLST), phylogenetic analysis, and real-time clonal and plasmid transmission detection.&nbsp;
SeqSphere+&nbsp;can handle data from various NGS instrument platforms. Financial details of the investment were not disclosed.
In October 2024, Bruker acquired Dynamic Biosensors GmbH, a biosensor development company <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41137534/bruker-acquires-dynamic-biosensors-a-pioneer-of-single-cell-interaction-cytometry-systems-for-drug" rel="noreferrer noopener">based in Munich, Germany</a>.
The acquisition strengthened Bruker&#8217;s biophysical portfolio for analyzing molecular interactions and kinetics.
Price Action: BRKR&#8217;s stock was up 2.47% at $39.01 during the premarket session on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44760665/blackrocks-bold-quarter-eps-tops-116t-aum-84b-inflows-power-growth" target="_blank" rel="noreferrer noopener">BlackRock&#8217;s Bold Quarter: EPS Tops, $11.6 Trillion AUM, $84 Billion Inflows Power Growth</a></li>
</ul>
Photo: Shutterstock

Large Cap

Health Care

Trading Ideas

General

Why Is Life Science Focused Bruker Stock Trading Higher On Friday?

WIIM

Bruker shares are trading higher after the company issued Q1 revenue guidance above consensus estimates and announced a partnership with Ridom for NGS bioinformatic applications.

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com%2F&amp;esheet=54236894&amp;newsitemid=20250411651079&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=1&amp;md5=7b4923def2a7cf98f667d9ab0904355d">Bruker Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) today announced preliminary revenue for the first quarter ended March 31, 2025, in a range of $795 million to $800 million, comparing favorably to the Company's earlier outlook and well ahead of consensus.
This estimated range implies reported revenue growth of approximately 10% year-over-year, with low-double digit percentage constant exchange rate revenue growth. Bruker estimates non-GAAP organic revenue growth in the first quarter to be in the low-single digit percentages, with mid-single digit percentage organic revenue growth in the Bruker Scientific Instrument (BSI) segment, and a high-teens percentage organic revenue decline in the BEST segment, net of intercompany eliminations.
Bruker expects to report its first quarter 2025 financial results before market opening on May 7, 2025.

Bruker Sees Q1 Revenue Between $795M And $800M, Well Ahead Of Consensus

Bruker To Partner With Ridom For NGS Bioinformatics Applications In Microbiology And Infectious Disease Testing

Barclays analyst Luke Sergott maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Overweight and lowers the price target from $60 to $50.

Barclays Maintains Overweight on Bruker, Lowers Price Target to $50

Citigroup analyst Patrick Donnelly maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Buy and lowers the price target from $75 to $50.

Citigroup Maintains Buy on Bruker, Lowers Price Target to $50

Bruker Launches 1.3 GHz High-Resolution Nuclear Magnetic Resonance System

Bruker Launches Fourier 80 Multinuclear Benchtop FT-NMR Spectrometer To Enable  X-Nucleus Observations And various 2D Experiments

Bruker Announces Introduction Of d-DNP Polarizer For MRI Research And For Dynamic Nuclear Polarization Liquids NMR

Press Releases

Bruker Introduces Innovative Fourier 80 Multinuclear Benchtop FT-NMR

Bruker Announces First-of-a-kind 1.3 GHz High-Resolution NMR System

Bruker Complements Fast, Cost-effective IR Biotyper® Hospital Hygiene Testing and HAI Tracing with NGS Reflex Testing

Bruker Announces First Quarter 2025 Preliminary Revenue

Bruker Announces Majority Acquisition of RECIPE, a Leading Provider of Mass Spectrometry-based Diagnostic Assay Kits for Therapeutic Drug Monitoring

Bruker Introduces nVista 2P Miniature Microscope

Management

Solis Agrosciences Names Crystal Winkeler Chief Business Officer to Drive Commercial Growth

Bruker to Launch Beacon Discovery™ at AACR 2025, Expanding Access to Live Single-Cell Functional Analysis

Bruker Spatial Biology Pushes Boundaries in Spatial Biology and Multiomics at AACR 2025

Bruker Reports First Quarter 2025 Financial Results

Agilent Technologies

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec

Illumina

IQVIA Hldgs

Medpace Hldgs

Mesa Laboratories

Mettler-Toledo International, Inc. Common Stock

Mettler-Toledo Intl

Niagen Bioscience

Repligen

Revvity

Sotera Health

Stevanato Group

Bio-Techne

Tempus AI

Thermo Fisher Scientific Inc Common Stock

Thermo Fisher Scientific

10x Genomics

Waters

West Pharmaceutical Services, Inc. Common Stock

West Pharmaceutical Servs

Barclays

Goldman Sachs

Stifel

Wells Fargo

지난주 이들 11개 대형주는 최하의 성과를 보여주었다. 여러분이 보유한 포트폴리오에도 이들이 있나요?
<ol>
<li>Arm 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>)는 지난주 가장 성과가 나쁜 대형주 기업으로 31.08% 폭락했다. 이 회사의 주가는 ASML 홀딩 N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>)이 예상보다 저조한 <a href="https://www.benzinga.com/news/24/04/38299189/whats-going-on-with-arm-holdings-stock" target="_blank" rel="noreferrer noopener">1분기 연간 실적 발표</a>에 영향을 받았다. 엑산 BNP 파리바(Exane BNP Paribas)의 데이비드 오코너(David O&#8217;Connor) 분석가는 ARM의 목표 가격을 100달러로 유지하며 등급을 <a href="https://www.benzinga.com/quote/ARM/analyst-ratings" target="_blank" rel="noreferrer noopener">&#8220;시장 수익률 상회(Outperform)&#8221;에서 &#8220;중립(Neutral)&#8221;으로 </a>하향 조정했다.</li>
<li>마이크로스트레티지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)의 주가는 지난주 20.07% 하락했다. 반감기를 앞둔 비트코인(CRYPTO:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/btc-usd" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for BTC/USD">BTC</a>) 가격의 변동성때문에 지난주 대부분의 암호화폐 주식이 하락했다.</li>
<li>코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)의 주식은 비트코인(CRYPTO:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/btc-usd" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for BTC/USD">BTC</a>) 가격의 약세로 인해 지난주 15%의 빠졌다. 경제학자인 피터 쉬프(Peter Schiff)는 일부 강세 예측에 맞춰 이 암호화폐가 상승할 것에 대해 회의적인 입장을 <a href="https://www.benzinga.com//node/38265256" target="_blank" rel="noreferrer noopener">표명했</a>다.</li>
<li>프롤로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>)의 주식은 13.73% 하락했다. 이 회사의 2024년 1분기 임대 수익은 18억 3천만 달러로 컨센서스를 하회했으며 예상되는 <a href="https://www.benzinga.com/news/earnings/24/04/38292399/why-prologis-shares-are-trading-lower-today" target="_blank" rel="noreferrer noopener">평균 점유율 감소와 경쟁적 임대</a>로 인해 EPS 및 핵심 FFO/주식에 대한 FY24 전망을 낮췄다.</li>
<li>테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)의 주식은 지난주 13.6% 하락했다. 일론 머스크가 이끄는 이 회사는 <a href="https://www.benzinga.com//node/38346490" target="_blank" rel="noreferrer noopener">여러 이유로</a> 힘든 1주일을 보냈다. 현재 하락하는 전기차 수요, 사이버트럭 리콜, 직원 감축 및 가격 인하에 직면하고 있다.</li>
<li>에퀴팩스(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/efx" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for EFX">EFX</a>)의 주식은 13.54% 빠졌다. 이 회사는 예상보다 나쁜 1분기 판매 실적을 보고했으며 수요일에 <a href="https://www.benzinga.com/news/earnings/24/04/38333254/equifax-analysts-cut-their-forecasts-after-q1-results" target="_blank" rel="noreferrer noopener">추정치보다 낮게 조정된 지침</a>을 발표했다.</li>
<li>브루커 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>)의 주식은 현금 3억 9,260만 달러 나노스트링 테크놀로지스(NanoString Technologies)의 인수를 발표한 후 주가가 11.90% 하락하는 등 힘든 한 주를 보냈다.</li>
<li>라이브 네이션 엔터테인먼트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>)는 11.76% 하락했다. 이 회사의 주식은 법무부가 해당 회사를 상대로 독점 금지 <a href="https://www.benzinga.com/news/24/04/38265894/live-nation-entertainment-groupon-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session" target="_blank" rel="noreferrer noopener">소송을</a> 제기할 것이라는 보도가 나오면서 주가는 하락세를 보였다.</li>
<li>아리스타 네트웍스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>)의 주가는 지난주 10.69% 하락했다. 최근 로젠블라트(Rosenblatt)의 분석가는 목표 가격 210달러로 주식을 &#8220;매도&#8221;로 <a href="https://www.benzinga.com//node/38220808" target="_blank" rel="noreferrer noopener">두 단계</a>  하향 조정했다.</li>
<li>J.B. 헌트 트랜스포트 서비스(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/jbht" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for JBHT">JBHT</a>)의 주가는 지난주 10.47% 하락했다. 1분기 수익은 하위 부문 <a href="https://www.benzinga.com/news/earnings/24/04/38287679/why-j-b-hunt-transport-shares-are-diving-today" target="_blank" rel="noreferrer noopener">총 매출 감소와 선적 감소</a>로 인해 컨센서스 예상치를 밑돌았다. 몇몇 분석가들은 실적 부진 이후 <a href="https://www.benzinga.com/quote/JBHT/analyst-ratings" target="_blank" rel="noreferrer noopener">주식 목표 가격</a>을 낮췄다.</li>
<li>앨버말(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>)의 주식은 지난주 리튬 가격의 변동성으로 인해 9%의 가치를 잃었다.</li>
</ol>
참고 자료: <a href="https://www.benzinga.com/news/earnings/24/04/38349264/tracking-last-weeks-top-performers-are-these-7-large-cap-stocks-in-your-portfolio" target="_blank" rel="noopener">지난주 최고 성과 추적: 이 7개의 대형주가 포트폴리오에 포함되어 있나요?</a>
사진: 셔터스톡

Comments

Bruker

뉴스

에 대한 최신 뉴스 Bruker (NASDAQ:BRKR) 주식

월요일, 4월 22, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌